Topics

Articles

How the ‘fight-for-the-dollar’ is coming and likely will impact the bundled pricing of industry stakeholders.

Breaking the Pharma Industry’s Bundled Pricing Arrangements

Corey Ford is the vice president of reimbursement and policy insights for AmerisourceBergen.

As we approach the one-year anniversary of the IRA being signed into law, questions remain about how the new law will reverberate changes across the biopharma industry.

What’s Next for Biopharma Under the Inflation Reduction Act

Medicare-eligible patients need to be enrolled in registry to get Medicare coverage for the anti-beta amyloid drug that is priced to cost $26,500 a year.

FDA Gives Alzheimer’s Drug Leqembi Full Approval. That Means Medicare Coverage But...

Micah Litow, Kalderos’ president and COO, discusses the importance of identifying and resolving noncompliant discount requests, along with addressing the gross-to-net gap for drug manufacturers.

Addressing Revenue Leakage

Recent lawsuits are challenging the constitutionality of provisions in the Inflation Reduction Act.

Industry Slams Medicare Price Negotiation Scheme

Panel explores challenges that could affect their development.

DIA 2023: The Future of Biosimilars, Interchangeables

Session offers a look into the Inflation Reduction Act’s impact on market conditions. 

DIA 2023: The Impact of the IRA

Session explores practicality of models for selling low-cost drugs.

DIA 2023: Solving the Drug Pricing Problem

Pharma company claims that the IRA’s drug pricing clauses violate the First and Fifth Amendments.

Merck Files Lawsuit Against Federal Government

Indicates that reimbursement for new slate of Alzheimer’s treatments will occur only with the completion of studies to support full approval.



Market Access